To determine the clinical relevance of G9a-translational mechanism that regulates AD proteopathology, and to predict MS1262 efficacy for treating AD patients, we compared our proteomic and phosphoproteomic data from non-treated versus MS1262-treated AD mice with the proteomic data of different cohorts of AD patients. This evidence concerns the gene EHMT2 and Alzheimer disease.